Immunotherapy in Melanoma | Specialty

Dr. Wolchok on the Safety Profile in CheckMate-067 in Melanoma

September 15th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the safety profile in the CheckMate-067 trial, which examined nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma.

Dr. D'Orazio on UV Signature Mutations in Melanoma

September 9th 2016

John A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.

Dr. Postow on the Current Treatment Landscape in Melanoma

September 8th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.

A Closer Look at BRAF Melanoma Testing Reveals Intricacies of V600 Mutation

September 5th 2016

BRAF mutation testing has become an essential tool in the diagnostic workup and management of patients with advanced melanoma. Activating mutations of BRAF are present in 40% to 60% of all melanoma cases, with more than 90% of mutations found at codon 600 in exon 15.

Expert Discusses Next Steps With Immunotherapy in Melanoma

September 2nd 2016

Yvonee Saenger, MD, discusses ongoing developments with immunotherapy in melanoma.

FDA Accepts Binimetinib NDA for NRAS-Mutant Melanoma

September 1st 2016

The FDA has assigned a standard review designation to a new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma.

Wolchok Discusses T-VEC, Other Immunotherapy Developments in Melanoma

August 25th 2016

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Dr. Keith T. Flaherty on the NEMO Trial in NRAS-Mutant Melanoma

August 23rd 2016

Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising

August 21st 2016

Treatment Options for Melanoma Outpace Data on How to Use Them

August 16th 2016

With several more melanoma treatments poised to emerge from the pipeline, data on the optimal way to incorporate these novel drugs into practice lag far behind the breakneck pace of approvals.

Immunotherapy Transforms Melanoma Care, But Challenges Remain

August 12th 2016

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

Dr. Reinhard Dummer on Toxicities with Binimetinib in Metastatic Melanoma

August 11th 2016

Final OS Analysis Confirms Cobimetinib/Vemurafenib Benefit in Melanoma

August 10th 2016

Combination therapy with cobimetinib (Cotellic) and vemurafenib (Zelboraf) reduced the risk of death by 30% compared with vemurafenib alone in patients with BRAF-positive advanced melanoma.

Weber Discusses Sequential Versus Concurrent Immunotherapy in Melanoma

August 9th 2016

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Fischkoff on Vision for TIL Therapy in Melanoma

August 3rd 2016

Steven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte therapy for patients with melanoma.

Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma

August 2nd 2016

Dr. Kaufman on Avelumab in Merkel Cell Carcinoma

July 28th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for clinical science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses the phase II JAVELIN Merkel 200 study examining avelumab as a treatment for patients with Merkel cell carcinoma.

Long-Term Follow-up Sustains Sonidegib Benefit in Basal Cell Carcinoma

July 20th 2016

The hedgehog inhibitor sonidegib (Odomzo) showed continued antitumor activity with no new safety concerns in patients with advanced basal cell carcinoma.

Large Trial Confirms Vismodegib Benefit in Basal Cell Carcinoma

July 19th 2016

The hedgehog inhibitor vismodegib (Erivedge) had an estimated disease control rate of 92.9% in the STEVIE trial, the largest ever study conducted in advanced basal cell carcinoma.

Dr. Ryan Sullivan on Treatment Options for Advanced Basal Cell Carcinoma

July 8th 2016